Hookipa H-200-001
Trial Overview
Official Title
: A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
Study Purpose
To determine whether HB-201 and HB-202 are effective in the treatment of HPV+ confirmed cancers.
Diagnosis
HPV+ Oropharyngeal CancerEligibility
Cancer growth or recurrence after 1-2 prior cancer treatment lines. Cancer tissue from biopsy after most recent treatment is required.
Intervention
Cohort D (at least 2 prior treatments): HB-202 & HB-201 rotating
Cohort E (at least 1 prior treatment): HB-202 & HB-201 rotating + pembrolizumab (Keytruda) +/- chemotherapy
Group F (at least 2 prior treatments): HB-202 & HB-201 rotating + pembrolizumab (Keytruda)
For more information, visit Clinicaltrials.gov
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase I